BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges
No Timetable in Sight
Executive Summary
An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.
You may also be interested in...
Applications Heavily Reliant On Foreign Data Get Positive Signals In US FDA Reviews
Agency has notably rejected some NDAs that relied solely on Chinese data, but a positive advisory committee for Geron’s proposed anemia treatment imetelstat and approval for BeiGene’s anti-PD-1 antibody Tevimbra suggest that using a lot of foreign data could be OK.
US Tevimbra Approval Validates BeiGene’s Asia-Heavy Global Trial Approach
BeiGene's first US approval for Tevimbra (tislelizumab), based on an Asia-heavy global study, is expected to pave the way for the biopharma to win two more approvals within 2024.
Growing Pains: Charting The Rapid Rise Of Chinese IO
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.